

# Patient Report

55210521505337

Doe, Patient

## Patient Details

DOB: 08/09/1989

Age(y/m/d): 34 years

Gender: F

Sample ID: 55210521505337

## Specimen Details

Date collected: 9/14/2023

Date received: 9/15/2023

Date reported: 9/16/2023

## Physician Details

Physician Name: Wildemore Bernadette

Client Name: 4U Health

## COVID-19 Antibody Test

Specimen Type: Dried Blood Spot

TESTS	RESULT	UNITS	REFERENCE RANGE
<b>Respiratory One</b>			
SARS-CoV-2 Semi-Quant Total Ab	SEE DILUTION	U/mL	Negative<0.8
SARS-CoV-2 Spike Ab Dilution	21546	U/mL	Negative<0.8
SARS-CoV-2 Spike Ab Interp	POSITIVE		
<p>Antibodies against the SARS-CoV-2 spike protein receptor binding domain (RBD) were detected. It is yet undetermined what level of antibody to SARS-CoV-2 spike protein correlates to immunity against developing symptomatic SARS-CoV-2 disease. Studies are underway to measure the quantitative levels of specific SARS-CoV-2 antibodies following vaccination. Such studies will provide valuable insights into the correlation between protection from vaccination and antibody levels. Roche Elecsys Anti-SARS-CoV-2 S</p>			

P23 LABS  
3095 Moon Station Road, Kennesaw, Georgia 30144

Dr. Wildemore | GA CLIA# 11D2182945 |  
P23LABS.COM

This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens.

Reviewed By: TM 09/16/2023 11:52:17 AM